1. China Stocks

  2. •

    Process industries

  3. •

    Chemicals: major diversified
Zhejiang Dayang Biotech Group Co., Ltd. Class A

Zhejiang Dayang Biotech Group Co., Ltd. Class A

SSZSE:003017
21.96
CNY
-2.29
(-9.44%)
2.32BMarket Cap
Zhejiang Dayang Biotech Group Co., Ltd. Class A
SZSE:003017
(Shenzhen Stock Exchange)

Recent

price

21.96

P/E

ratio

- -

div

yld

2.45%

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
9.04
8.27
8.11
7.84
8.54
8.3
8.24
8.51
7.77
15.15
9.49
9.3
10.69
- -
Revenue per Share
0.48
0.51
0.43
0.51
0.77
1.01
1.05
1.15
0.69
1.16
0.52
0.65
1.02
- -
Basic EPS, GAAP
0.91
0.34
0.1
0.6
0.34
-0.08
0.68
-0.15
-1.28
-0.18
0.81
0.03
0.86
- -
Free Cash Flow per Basic Share
0.34
0.34
0.17
0.4
0.42
0.33
0.32
0.18
0.38
0.56
0.44
0.44
0.56
0.54
Dividend per Share
3
3.3
3.4
3.9
4.84
5.83
6.59
9.51
9.83
9.77
10
10.44
11.23
11.62
Book Value per Share
2.51
2.82
2.8
3.31
4.29
5.06
5.82
8.94
9.27
8.83
9.08
9.53
10.37
10.65
Tangible Book Value per Share
55
55
55
56
65
70
75
80
101
70
97
98
98
98
Basic Weighted Avg Shares
500
459
448
441
555
584
622
678
783
1,058
919
910
1,045
- -
Sales/Revenue/Turnover
7.17
4.75
5.32
5.89
12.49
14.12
14.2
15.36
9.36
5.36
6.82
8.87
11.78
- -
Operating Margin (%)
20
20
21
23
24
26
30
31
45
60
70
69
73
- -
Depreciation Expense
26
28
24
29
50
71
79
92
70
81
50
64
100
- -
Net Income, GAAP
3.63
1.98
2.49
7.05
9.25
5.79
8.34
8.63
8.05
- -
- -
11.04
6.35
- -
Effective Tax Rate (%)
5.27
6.12
5.28
6.53
9.06
12.12
12.79
13.5
8.94
7.63
5.44
7.01
9.55
- -
Profit Margin (%)
-22
-39
-41
-33
60
123
135
497
426
250
231
123
139
1
Working Capital
- -
- -
- -
- -
- -
- -
- -
52
41
- -
69
- -
22
38
LT Debt
177
195
200
229
338
441
498
958
991
985
1,008
1,053
1,137
1,176
Total Equity
- -
2.13
4.21
4.56
13.67
17.09
16.34
12.31
6.75
- -
- -
5.03
7.07
- -
Return on Invested Capital (%)
- -
10.62
9.24
9.82
14.77
16.8
16.45
12.05
6.74
- -
- -
5.21
7.09
- -
Return on Capital (%)
- -
15.15
12.01
13.43
17.73
18.19
16.94
12.58
7.18
8.17
5.02
6.19
9.14
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
345
378
414
LT Borrowings
20
28
37
LT Finance Leases
2
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
101
101
101
Market Capitalization
2,508
2,558
2,318

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
771
798
737
Cash, Cash Equivalents & STI
460
462
398
Accounts Receivable, Net
87
126
97
Inventories
108
112
136
Total Current Liabilities
633
651
735
Payables & Accruals
- -
- -
- -
ST Debt
345
378
414
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.53%
3.52%
7.94%
Free Cash Flow
216.21%
597.95%
2,950.92%
Net Income, GAAP
20.24%
7.56%
56.64%
Sales/Revenue/Turnover
9.64%
10.26%
14.89%
Total Cash Common Dividend
32.22%
42.31%
27.98%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
195
242
235
238
910
2025
249
250
- -
298
1,045
2026
278
281
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
0.15
0.2
0.13
0.65
2025
0.3
0.21
- -
0.2
1.02
2026
0.32
0.27
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.02
0.42
-0.02
0.44
2025
0.01
0.27
- -
0.27
0.56
2026
0.01
0.26
- -
- -
- -
Similar Companies
Hektas Ticaret T.A.S. (BIST:HEKTS)
Aether Industries Ltd. (NSE:AETHER)
AARTI Industries Ltd (NSE:AARTIIND)
Mitsui & Co.,Ltd (TSE:8031)
Saudi Basic Industries Corp. (TADAWUL:2010)
Raghav Productivity Enhancers Ltd. (NSE:RPEL)
Business
Zhejiang Dayang Biotech Group Co., Ltd. (003017.SZ) manufactures and sells chemical raw materials, focusing on inorganic salts, veterinary drug active pharmaceutical ingredients and fluorine-containing fine chemicals; its core products include food additive, industrial, agricultural and feed grade potassium carbonate and potassium bicarbonate, ammonium chloride, amprolium hydrochloride (with US FDA and veterinary GMP certification), ceftiofur sodium and hydrochloride, cefquinome sulfate, decoquinate, colistin sulphate B, 2-chloro-6-fluorobenzaldehyde, 2-chloro-6-fluorobenzyl chloride and other fluorine series; the company operates from its headquarters in Jiande City, Zhejiang Province, China, exporting to dozens of countries across the Americas, Africa, Europe and Southeast Asia. Founded in 1976 and listed on the Shenzhen Stock Exchange main board in 2020, the company maintains a "one body two wings" structure centered on potash products with veterinary drugs and fine chemicals; it holds certifications including ISO9001, ISO14001, ISO22000 and ISO45001, and operates provincial research centers, postdoctoral workstation and potassium salt institute as a national high-tech enterprise and drafter of Chinese potassium carbonate standards. Recent developments feature expansion of amprolium hydrochloride capacity to 800 tons annually by mid-2026 alongside full utilization of existing 600 tons, pilot production of PEEK intermediates like difluorobenzophenone leveraging fluorobenzene facilities, a 2025 equity incentive plan granting up to 0.994 million restricted shares, projected first-half 2025 net profit growth of 43-75% year-over-year and new materials focus on lightweight potassium carbonate and fluorine chemicals amid rising hydrochloride aminopropyl demand.